Regeneron Pharmaceuticals (REGN) Earnings Date & Reports

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

REGN is expected to report earnings to rise 4.62% to $8.60 per share on July 31

Regeneron Pharmaceuticals REGN Stock Earnings Reports

Q2'25

Est.

$8.60

Q1'25

Missed

by $0.26

Q4'24

Beat

by $0.80

Q3'24

Beat

by $0.74

Q2'24

Beat

by $0.95

The last earnings report on April 29 showed earnings per share of $8.22, missing the estimate of $8.48. With 1.15M shares outstanding, the current market capitalization sits at 61.99B.

View a ticker or compare two or three

Compare

REGN